

DAFTAR PUSTAKA

- Aisyi, M., Syarif, A. H., Anggraeni, N. A., Perdana, A. B., Rezky, H., Kosasih, A., & Basuki, A. (2019). Survival Analysis in Pediatric Osteosarcoma. *Indonesian Journal of Cancer*, *13*(2), 21-24.
- Chen, W., & Lin, Y. (2019). Nomograms predicting overall survival and cancer-specific survival in osteosarcoma patients (STROBE). *Medicine*, *98*(26).
- D.M Fletcher, C. *et al.* (2013) . WHO Classification of Tumours of Soft Tissue and Bone. *Internasional Agency for Research on Cancer*, pp. 281–295.
- Dai, M., Zhang, C., Ali, A., Hong, X., Tian, J., Lo, C., & Lebrun, J. J. (2016). CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer. *Scientific reports*, *6*, 35383.
- Faisham, W. I., Mat Saad, A. Z., Alsaigh, L. N., Nor Azman, M. Z., Kamarul Imran, M., Biswal, B. M., & Ariffin, N. (2017). Prognostic factors and survival rate of osteosarcoma: A single- institution study. *Asia- Pacific Journal of Clinical Oncology*, *13*(2), e104-e110.
- Geller, D. S., & Gorlick, R. (2010). Osteosarcoma: a review of diagnosis, management, and treatment strategies. *Clin Adv Hematol Oncol*, *8*(10), 705-718.
- Hamilton, E., & Infante, J. R. (2016). Targeting CDK4/6 in patients with cancer. *Cancer treatment reviews*, *45*, 129-138.
- Hornick, J. (2013). Pactical soft tissue pathology. *A Diagn Appr Elsevier*, *16*, 437-438.

- Houts, P. S. et al, (2019). ACS cancer facts and figures. *Cancer Practice*, 8(3), pp. 105–108.
- Jiang, Q., Mai, C., Yang, H., Wu, Q., Hua, S., Yan, C., & Liu, Z. (2014). Nuclear expression of CDK 4 correlates with disease progression and poor prognosis in human nasopharyngeal carcinoma. *Histopathology*, 64(5), 722-730.
- Kamal, A. F., Widyawarman, H., Husodo, K., Hutagalung, E. U., & Rajabto, W. (2016). Clinical outcome and survival of osteosarcoma patients in Cipto Mangunkusumo Hospital: limb salvage surgery versus amputation. *Acta Medica Indonesiana*, 48(3), 175-183.
- Kennedy, A. L., Vallurupalli, M., Chen, L., Crompton, B., Cowley, G., Vazquez, F., & Alexe, G. (2015). Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. *Oncotarget*, 6(30), 30178.
- Kim, M. S., Lee, S. Y., Cho, W. H., Song, W. S., Koh, J. S., Lee, J. A., ... & Jeon, D. G. (2008). Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. *Journal of surgical oncology*, 97(5), 456-461.
- Komite Penanggulangan Kanker Nasional (2015). Panduan Penatalaksanaan Osteosarkoma, *Komite Penanggulangan Kanker Nasional*, pp. 1–40. Available at: <http://kanker.kemkes.go.id/guidelines/PPKOsteosarkoma.pdf>.
- Kyriazoglou, A. I., Vieira, J., Dimitriadis, E., Arnogiannaki, N., Teixeira, M. R.,

- & Pandis, N. (2012). 12q amplification defines a subtype of extraskeletal osteosarcoma with good prognosis that is the soft tissue homologue of parosteal osteosarcoma. *Cancer Genetics*, 205(6), 332-336.
- Lee, S., Park, H., Ha, S. Y., Paik, K. Y., Lee, S. E., Kim, J. M., & Kim, S. J. (2014). CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen. *PloS one*, 9(8), e99452.
- Li, W., & Zhang, S. (2018). Survival of patients with primary osteosarcoma and lung metastases. *JBUON*, 23(5), 1500-1504.
- Lin, P. P., & Patel, S. (2013). Osteosarcoma. In *Bone Sarcoma*. Springer, Boston, MA. (pp. 75-97).
- Liu, D. (2017). Tumors and Cancers: Skin–Soft Tissue–Bone–Urogenitals. *CRC Press*. 17(8), pp. 83–88.
- Liu, T., Shen, J. K., Choy, E., Zhang, Y., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2018). CDK4 expression in chordoma: a potential therapeutic target. *Journal of Orthopaedic Research®*, 36(6), 1581-1589.
- Longhi, A., Errani, C., De Paolis, M., Mercuri, M., & Bacci, G. (2006). Primary bone osteosarcoma in the pediatric age: state of the art. *Cancer treatment reviews*, 32(6), 423-436.
- Maitra, A., Roberts, H., Weinberg, A. G., & Geradts, J. (2001). Loss of p16INK4a expression correlates with decreased survival in pediatric osteosarcomas. *International journal of cancer*, 95(1), 34-38.
- Mankin, H. J., Hornicek, F. J., Rosenberg, A. E., Harmon, D. C., & Gebhardt, M. C. (2004). Survival data for 648 patients with osteosarcoma treated at one

institution. *Clinical Orthopaedics and Related Research*®, 429, 286-291.

Miller, B. J., Cram, P., Lynch, C. F., & Buckwalter, J. A. (2013). Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. *The Journal of bone and joint surgery. American volume*, 95(13).

Mirabello, L., Troisi, R. J., & Savage, S. A. (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 115(7), 1531-1543.

Misaghi, A., Goldin, A., Awad, M., & Kulidjian, A. A. (2018). Osteosarkoma: a comprehensive review. *Sicot-j*, 4.

Mitchell, RN, Kumar, V., Abbas, AK, & Aster, JC (Eds.). (2017). Robbins basic pathology. Elsevier Health Sciences.

Moore, D. D., & Luu, H. H. (2014). Osteosarcoma. In *Orthopaedic oncology* (pp. 65-92). Springer, Cham.

Nie, Z., & Peng, H. (2018). Osteosarkoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes. *Oncology letters*, 16(5), 6502-6514.

Nielsen, G. P., & Rosenberg, A. E. (2017). *Diagnostic pathology: bone*. Elsevier Health Sciences.

O'leary, B., Finn, R. S., & Turner, N. C. (2016). Treating cancer with selective CDK4/6 inhibitors. *Nature reviews Clinical oncology*, 13(7), 417-430.

Olanich, M. E., Sun, W., Hewitt, S. M., Abdullaev, Z., Pack, S. D., & Barr, F. G.

- (2015). CDK4 amplification reduces sensitivity to CDK4/6 inhibition in fusion-positive rhabdomyosarcoma. *Clinical Cancer Research*, 21(21), 4947-4959.
- Ottaviani, G., & Jaffe, N. (2009). The epidemiology of osteosarcoma. In *Pediatric and adolescent osteosarkoma* (pp. 3-13). Springer, Boston, MA.
- Perez, M., Muñoz-Galván, S., Jiménez-García, M. P., Marín, J. J., & Carnero, A. (2015). Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. *Oncotarget*, 6(38), 40557.
- Pytel, P., & Cilaki-lakini, N. A. (2018). Soft Tissue and Bone Neoplasms. In *Precision Molecular Pathology of Neoplastic Pediatric Diseases*. Springer, Cham. pp. 169-193.
- Sakamoto, A., & Iwamoto, Y. (2008). Current status and perspectives regarding the treatment of osteosarcoma: chemotherapy. *Reviews on recent clinical trials*, 3(3), 228-231.
- Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., & Antal, I. (2019). Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarkoma Study) cohort. *European Journal of Cancer*, 109, 36-50.
- Taran, S. J., Taran, R., & Malipatil, N. B. (2017). Pediatric osteosarcoma: an updated review. *Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology*, 38(1), 33.

- Vasquez, L., Tarrillo, F., Oscanoa, M., Maza, I., Geronimo, J., Paredes, G., & Sialer, L. (2016). Analysis of prognostic factors in high-grade osteosarcoma of the extremities in children: a 15-year single-institution experience. *Frontiers in oncology*, 6, 22.
- Wang, S. W., Wu, H. H., Liu, S. C., Wang, P. C., Ou, W. C., Chou, W. Y., & Tang, C. H. (2012). CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. *PloS one*, 7(4), e35101.
- Wang, Z., Wu, B., Zhou, Y., Huang, X., Pan, W., Liu, M., & Ye, Z. (2019). Predictors of the Survival of Primary and Secondary Older Osteosarcoma Patients. *Journal of Cancer*, 10(19), 4614.
- Wei, G., Lonardo, F., Ueda, T., Kim, T., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1999). CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. *International journal of cancer*, 80(2), 199-204.
- Wu, J., Sun, H., Li, J., Guo, Y., Zhang, K., Lang, C., & Ma, H. (2018). Increased survival of patients aged 0- 29 years with osteosarcoma: A period analysis, 1984- 2013. *Cancer medicine*, 7(8), 3652-3661.
- Yoshida, A., Ushiku, T., Motoi, T., Beppu, Y., Fukayama, M., Tsuda, H., & Shibata, T. (2012). MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. *The American journal of surgical pathology*, 36(3), 423-431.
- Zhou, Y., Shen, J. K., Yu, Z., Hornicek, F. J., Kan, Q., & Duan, Z. (2018). Expression and therapeutic implications of cyclin-dependent kinase 4

(CDK4) in osteosarcoma. *Biochimica et Biophysica Acta (BBA)-Molecular*

Basis of Disease, 1864(5), 1573-1582.